Summary & Overview
HCPCS G8582: Beta-blocker at Discharge
HCPCS Level II code G8582 denotes the provision of a beta-blocker at patient discharge. This code captures a common discharge medication strategy intended to continue or initiate beta-adrenergic blockade following an inpatient or observation stay for conditions where beta-blockade is indicated. Nationally, discharge medication documentation affects transitions of care, quality measurement, and pharmacy reconciliation processes across hospitals and health systems.
Key payers covered in this review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, expected site of service, and typical service type. The publication outlines benchmarking considerations, policy and documentation implications for payers and providers, and how G8582 integrates into discharge workflows and quality reporting. Where specific data elements were not provided, the report notes that input information was unavailable. This summary is intended for national audiences involved in billing operations, clinical quality, and revenue cycle management who need a clear reference on the purpose and use of HCPCS Level II code G8582.
Billing Code Overview
HCPCS Level II code G8582 represents Beta-blocker at discharge. This code is used to document and bill for the provision of a beta-blocker medication at the time a patient is discharged from care.
-
Service type: Medication reconciliation and discharge pharmacotherapy
-
Typical site of service: Hospital inpatient discharge or observation discharge
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult hospitalized after an acute myocardial infarction (AMI) or diagnosed with left ventricular systolic dysfunction who is medically stabilized and ready for discharge. During the inpatient discharge workflow, the treating cardiologist or hospitalist documents initiation or confirmation of a beta‑blocker medication on the discharge medication list and in the discharge summary. The pharmacotherapy may be a continuation of preadmission therapy or a new prescription started for secondary prevention of ischemic heart disease, heart failure management, or rate control for arrhythmias. Nursing reconciliation checks the medication, pharmacy processes the discharge prescription, and outpatient follow‑up is arranged with cardiology or primary care for dose titration and monitoring of blood pressure and heart rate. Payers involved in claims review include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day | Use when a separate E/M visit is provided and documented on the discharge day in addition to the discharge medication reconciliation. |
59 |